Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Novo Nordisk hires US pharma veteran as Trump pricing pressure mounts
    Finance

    Novo Nordisk hires US pharma veteran as Trump pricing pressure mounts

    Published by Global Banking & Finance Review®

    Posted on October 17, 2025

    1 min read

    Last updated: January 21, 2026

    Novo Nordisk hires US pharma veteran as Trump pricing pressure mounts - Finance news and analysis from Global Banking & Finance Review
    Tags:Appointmentpharmaceutical marketfinancial communitycorporate governance

    Quick Summary

    Novo Nordisk hires Greg Miley as head of corporate affairs amid rising drug pricing pressures from the Trump administration.

    Table of Contents

    • Novo Nordisk's New Leadership
    • Background on Greg Miley
    • Challenges in the Pharmaceutical Market

    Novo Nordisk Appoints Greg Miley Amid Rising Pricing Pressures

    Novo Nordisk's New Leadership

    LONDON/COPENHAGEN (Reuters) -Novo Nordisk has appointed U.S. pharmaceutical executive Greg Miley as its new head of corporate affairs, according to a statement he posted on LinkedIn, as the obesity drugmaker faces growing pressure from the Trump administration on drug pricing.

    Background on Greg Miley

    Miley, an American, is currently senior vice president of government affairs at U.S. pharmaceutical giant AbbVie. He posted the statement on LinkedIn on Friday and Novo Nordisk shared the statement with Reuters.

    Challenges in the Pharmaceutical Market

    (Reporting by Maggie Fick in London and Stine Jacobsen in Copenhagen, Editing by Louise Heavens)

    Key Takeaways

    • •Novo Nordisk appoints Greg Miley as head of corporate affairs.
    • •Greg Miley is a senior vice president at AbbVie.
    • •Novo Nordisk faces pressure from Trump administration on drug pricing.
    • •The appointment was announced on LinkedIn and shared with Reuters.
    • •Novo Nordisk is a leading obesity drugmaker.

    Frequently Asked Questions about Novo Nordisk hires US pharma veteran as Trump pricing pressure mounts

    1What is corporate affairs?

    Corporate affairs refers to the management of a company's interactions with its stakeholders, including shareholders, employees, and the public, often focusing on communication and reputation management.

    2What is drug pricing?

    Drug pricing involves the determination of the cost of pharmaceuticals, influenced by factors such as production costs, market demand, and regulatory policies.

    3What is a pharmaceutical executive?

    A pharmaceutical executive is a senior professional in the pharmaceutical industry responsible for strategic decision-making, overseeing operations, and ensuring compliance with regulations.

    4What is a LinkedIn statement?

    A LinkedIn statement is a public post or update shared on LinkedIn, often used by professionals to announce career changes, achievements, or company news.

    5What is the role of the Trump administration in drug pricing?

    The Trump administration sought to influence drug pricing through various policies aimed at reducing costs for consumers and increasing transparency in pharmaceutical pricing.

    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Previous Finance PostAixtron says 2025 sales to be at lower end of guidance
    Next Finance PostBank of Italy cuts Italian 2026 growth outlook on US tariffs, strong euro
    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts